Industry news

Drug labeling allowed to detect illegal resale of expensive medicines

GMP News

A joint operation conducted by the Main Directorate for Economic Security and Countering Corruption of the Russian Ministry of Internal Affairs, the Department for Economic Security and Countering Corruption of the Russian Ministry of Internal Affairs for St. Petersburg and the Leningrad Region, together with the employees of Roszdravnadzor, uncovered the illegal resale of expensive drugs MabThera and Acerbia, previously shipped to the City Clinical Oncological Dispensary of Saint-Petersburg, a state budgetary healthcare institution, and other medical institutions of the region under the 7 Nosologies, a federal program.

Mutual recognition agreement between EU and US brought into action

GMP News

1 November 2017 marks the coming into operation of further aspects of the mutual recognition agreement between the European Union (EU) and the United States (US) to recognise inspections of manufacturing sites for human medicines conducted in their respective territories. This agreement, which updates the agreement from 1998, allows for recognition of each other’s inspection outcomes and hence for better use of inspection expertise and resources.

Russia rises in World Bank’s Doing Business ranking

Marchmont Innovation News

Russia advanced five points to the 35th place in the World Bank’s annual  Doing Business report  released yesterday, a sixth consecutive year of improvement, reported US-Russia Business Council, citing the source. 

Advanced multiple myeloma drug candidate gets Russian backing

Marchmont Innovation News

Primer Capital, a Russian biotech-focused VC fund, earlier this year supported the development of a drug candidate by Russian company Hemopharm to help multiple myeloma patients. The investment was to fund preclinical trials. 

02 November 2017

Epic Sciences Launches Single-Cell Microsatellite and Chromosomal Instability Genomic Analysis

Epic Sciences, Inc. adds simultaneous microsatellite instability (MSI) and chromosomal instability (CIN) measurements, also known as genomic scarring analysis, to the single cell next generation sequencing (NGS) workflow for clinical research of immuno-oncology therapies. MSI is currently utilized to identify patients who may respond to PD-1 checkpoint inhibitors across multiple cancer indications. 

Vaccination will become a driver of economic growth in the 21st century

GMP News

Speaking at the Congress of the National Medical Chamber, Nikolai Briko, the Academician of RAS, Professor, Doctor of Medical Sciences and Member of the Scientific and Technical Council of Nacimbio, said that this century is the age of vaccines, and the objectives of preventive vaccination are expanding significantly.

11028 foreign and 5285 local patents are registered in the Russian Federation

GMP News

20 decisions on disputes related to patent rights in the area of pharmaceuticals have been made in 10 months of 2017. This was announced by Viktoriya Galkovskaya, the Head of Patent Law Division of Rospatent, at the RBC Pharma Forum.

EMA advised a set of indicators to confront antimicrobial resistance

GMP News

A set of indicators will assist European Union (EU) Member States to assess their progress in reducing the use of antimicrobials and combatting antimicrobial resistance (AMR). These indicators have been established by the European Food Safety Authority (EFSA), the European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC), following a request from the European Commission.

Capabilities of Russian medical equipment were showcased to cardiologists

GMP News

The Russian National Congress of Cardiology attended by international participants is currently taking place in St. Petersburg. Its scientific program is devoted to professional education, science, and innovation. The event includes an exhibition of medicines, equipment for diagnosis and treatment, where the Russian Ministry of Industry and Trade presented the new products of Russian manufacturers for diagnosis and treatment of cardiovascular diseases.

31 October 2017

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its financial results for the quarter ended September 30, 2017.